Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.

Novo Nordisk B

Ylin-
Alin-
Vaihto-
2026 Q2 -tulosraportti
11 päivää sitten
3,75 DKK/osake
Viimeisin osinko
3,97%Tuotto/v

Tarjoustasot

Ei dataa

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q3 -tulosraportti
4.11.
Menneet tapahtumat
2026 Q2 -tulosraportti
5.8.
2026 Q1 -tulosraportti
6.5.
Vuosittainen yhtiökokous 2026
26.3.
2025 Q4 -tulosraportti
4.2.
Ylimääräinen yhtiökokous 2025
14.11.2025

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 5 t sitten · Muokattu
    ·
    Novo director defends himself after criticism When the Danish pharmaceutical giant Novo Nordisk recently delivered its latest financial report, it once again caused the stock price to fall. And that led CEO Mike Doustdar to declare that Novo needs to move at a "completely different pace". - It requires more work. It requires one to get up earlier and go to bed later, said the CEO at Novo Nordisk at an online press conference. Subsequently, DR has had two trade unions criticize the director's statements as 'unworthy' and 'a harsh signal' about the work culture. But the director apparently does not share that view himself. On LinkedIn, he rejects the criticism Saturday evening. - Despite the impressive title, I am far too small a cog to be able to change such a strong culture as Novo Nordisk's on my own. - Over the past year, I have also learned that when one is in the spotlight, one's words and actions will be interpreted and judged by both people who know one well and people who do not. It comes with the job, and I accept that, he writes in a comment to a post” https://www.linkedin.com/posts/morten-tind-abildlund-907b09146_there-has-been-a-lot-of-discussion-in-the-activity-7494356605363310592-0d3J
    32 min sitten
    I agree 💯 with Mike
  • 7 t sitten
    ·
    Novo Nordisk is a big disappointment for me. Right now it stands at - 27000 kr. 😭😭Can one even get +27000 from a stock. Very difficult, I think. Fortunately, Microsoft has risen. The two hit me at one point - 60000 kr. 😂😂
  • 10 t sitten
    ·
    When is the dividend available in our account ?
    9 t sitten · Muokattu
    ·
    18. August. You can see it under overview :)
  • 12 t sitten
    ·
    Would not buy in unless we see something new and promising from novo nordisk
    10 t sitten
    ·
    Shared in 6430
  • 14 t sitten
    ·
    I bought more Novo Nordisk shares Thursday and Friday because they are strongly undervalued. And because a fall of minus 10% on better-than-expected financial results with several upgrades, including increasing pill sales, lacks connection to the actual facts. https://seekingalpha.com/article/4935329-the-market-is-still-underestimating-novo-nordisk
    9 t sitten
    ·
    Insider-abe Jim Cramer reevaluates Novo Nordisk (NVO) as Wegovy pill adoption accelerates Syeda Seirut Javed Saturday, August 15, 2026 at 02:42 GMT+3 4 minutes read NVO -1.78% Shares in the Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) experienced strong volatility after the latest quarterly results. In the August 12 Mad Money episode, Jim Cramer pointed out the gap between the company's strong performance and Wall Street's initial negative knee-jerk reaction. Cramer commented: "Okay, what happened to the shares of Novo Nordisk, the Danish pharmaceutical company, you know, as the inventor of Ozempic and Wegovy. Last week, they reported a beat and raise quarter, but the stock fell almost 6% that day the numbers were released. Since then, it has recovered most of the losses, but it was a surprising reaction. Hey, remember, Novo Nordisk helped invent the entire GLP-1 category, and their obesity and diabetes businesses are now printing money. In January, they launched a pill version of Wegovy. It has already been prescribed more than 5 million times, mostly to people who have never tried the injections. In the end, however, it's a turnaround story... but it still doesn't get much love from Wall Street." https://finance.yahoo.com/healthcare/articles/jim-cramer-reevaluates-novo-nordisk
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2026 Q2 -tulosraportti
11 päivää sitten
3,75 DKK/osake
Viimeisin osinko
3,97%Tuotto/v

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 5 t sitten · Muokattu
    ·
    Novo director defends himself after criticism When the Danish pharmaceutical giant Novo Nordisk recently delivered its latest financial report, it once again caused the stock price to fall. And that led CEO Mike Doustdar to declare that Novo needs to move at a "completely different pace". - It requires more work. It requires one to get up earlier and go to bed later, said the CEO at Novo Nordisk at an online press conference. Subsequently, DR has had two trade unions criticize the director's statements as 'unworthy' and 'a harsh signal' about the work culture. But the director apparently does not share that view himself. On LinkedIn, he rejects the criticism Saturday evening. - Despite the impressive title, I am far too small a cog to be able to change such a strong culture as Novo Nordisk's on my own. - Over the past year, I have also learned that when one is in the spotlight, one's words and actions will be interpreted and judged by both people who know one well and people who do not. It comes with the job, and I accept that, he writes in a comment to a post” https://www.linkedin.com/posts/morten-tind-abildlund-907b09146_there-has-been-a-lot-of-discussion-in-the-activity-7494356605363310592-0d3J
    32 min sitten
    I agree 💯 with Mike
  • 7 t sitten
    ·
    Novo Nordisk is a big disappointment for me. Right now it stands at - 27000 kr. 😭😭Can one even get +27000 from a stock. Very difficult, I think. Fortunately, Microsoft has risen. The two hit me at one point - 60000 kr. 😂😂
  • 10 t sitten
    ·
    When is the dividend available in our account ?
    9 t sitten · Muokattu
    ·
    18. August. You can see it under overview :)
  • 12 t sitten
    ·
    Would not buy in unless we see something new and promising from novo nordisk
    10 t sitten
    ·
    Shared in 6430
  • 14 t sitten
    ·
    I bought more Novo Nordisk shares Thursday and Friday because they are strongly undervalued. And because a fall of minus 10% on better-than-expected financial results with several upgrades, including increasing pill sales, lacks connection to the actual facts. https://seekingalpha.com/article/4935329-the-market-is-still-underestimating-novo-nordisk
    9 t sitten
    ·
    Insider-abe Jim Cramer reevaluates Novo Nordisk (NVO) as Wegovy pill adoption accelerates Syeda Seirut Javed Saturday, August 15, 2026 at 02:42 GMT+3 4 minutes read NVO -1.78% Shares in the Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) experienced strong volatility after the latest quarterly results. In the August 12 Mad Money episode, Jim Cramer pointed out the gap between the company's strong performance and Wall Street's initial negative knee-jerk reaction. Cramer commented: "Okay, what happened to the shares of Novo Nordisk, the Danish pharmaceutical company, you know, as the inventor of Ozempic and Wegovy. Last week, they reported a beat and raise quarter, but the stock fell almost 6% that day the numbers were released. Since then, it has recovered most of the losses, but it was a surprising reaction. Hey, remember, Novo Nordisk helped invent the entire GLP-1 category, and their obesity and diabetes businesses are now printing money. In January, they launched a pill version of Wegovy. It has already been prescribed more than 5 million times, mostly to people who have never tried the injections. In the end, however, it's a turnaround story... but it still doesn't get much love from Wall Street." https://finance.yahoo.com/healthcare/articles/jim-cramer-reevaluates-novo-nordisk
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Ei dataa

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q3 -tulosraportti
4.11.
Menneet tapahtumat
2026 Q2 -tulosraportti
5.8.
2026 Q1 -tulosraportti
6.5.
Vuosittainen yhtiökokous 2026
26.3.
2025 Q4 -tulosraportti
4.2.
Ylimääräinen yhtiökokous 2025
14.11.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

2026 Q2 -tulosraportti
11 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q3 -tulosraportti
4.11.
Menneet tapahtumat
2026 Q2 -tulosraportti
5.8.
2026 Q1 -tulosraportti
6.5.
Vuosittainen yhtiökokous 2026
26.3.
2025 Q4 -tulosraportti
4.2.
Ylimääräinen yhtiökokous 2025
14.11.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

3,75 DKK/osake
Viimeisin osinko
3,97%Tuotto/v

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 5 t sitten · Muokattu
    ·
    Novo director defends himself after criticism When the Danish pharmaceutical giant Novo Nordisk recently delivered its latest financial report, it once again caused the stock price to fall. And that led CEO Mike Doustdar to declare that Novo needs to move at a "completely different pace". - It requires more work. It requires one to get up earlier and go to bed later, said the CEO at Novo Nordisk at an online press conference. Subsequently, DR has had two trade unions criticize the director's statements as 'unworthy' and 'a harsh signal' about the work culture. But the director apparently does not share that view himself. On LinkedIn, he rejects the criticism Saturday evening. - Despite the impressive title, I am far too small a cog to be able to change such a strong culture as Novo Nordisk's on my own. - Over the past year, I have also learned that when one is in the spotlight, one's words and actions will be interpreted and judged by both people who know one well and people who do not. It comes with the job, and I accept that, he writes in a comment to a post” https://www.linkedin.com/posts/morten-tind-abildlund-907b09146_there-has-been-a-lot-of-discussion-in-the-activity-7494356605363310592-0d3J
    32 min sitten
    I agree 💯 with Mike
  • 7 t sitten
    ·
    Novo Nordisk is a big disappointment for me. Right now it stands at - 27000 kr. 😭😭Can one even get +27000 from a stock. Very difficult, I think. Fortunately, Microsoft has risen. The two hit me at one point - 60000 kr. 😂😂
  • 10 t sitten
    ·
    When is the dividend available in our account ?
    9 t sitten · Muokattu
    ·
    18. August. You can see it under overview :)
  • 12 t sitten
    ·
    Would not buy in unless we see something new and promising from novo nordisk
    10 t sitten
    ·
    Shared in 6430
  • 14 t sitten
    ·
    I bought more Novo Nordisk shares Thursday and Friday because they are strongly undervalued. And because a fall of minus 10% on better-than-expected financial results with several upgrades, including increasing pill sales, lacks connection to the actual facts. https://seekingalpha.com/article/4935329-the-market-is-still-underestimating-novo-nordisk
    9 t sitten
    ·
    Insider-abe Jim Cramer reevaluates Novo Nordisk (NVO) as Wegovy pill adoption accelerates Syeda Seirut Javed Saturday, August 15, 2026 at 02:42 GMT+3 4 minutes read NVO -1.78% Shares in the Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) experienced strong volatility after the latest quarterly results. In the August 12 Mad Money episode, Jim Cramer pointed out the gap between the company's strong performance and Wall Street's initial negative knee-jerk reaction. Cramer commented: "Okay, what happened to the shares of Novo Nordisk, the Danish pharmaceutical company, you know, as the inventor of Ozempic and Wegovy. Last week, they reported a beat and raise quarter, but the stock fell almost 6% that day the numbers were released. Since then, it has recovered most of the losses, but it was a surprising reaction. Hey, remember, Novo Nordisk helped invent the entire GLP-1 category, and their obesity and diabetes businesses are now printing money. In January, they launched a pill version of Wegovy. It has already been prescribed more than 5 million times, mostly to people who have never tried the injections. In the end, however, it's a turnaround story... but it still doesn't get much love from Wall Street." https://finance.yahoo.com/healthcare/articles/jim-cramer-reevaluates-novo-nordisk
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Ei dataa

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt